Phase IIa trial of ARC 1905 and E 10030 in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of anti-VEGF resistant wet age-related macular degeneration

Trial Profile

Phase IIa trial of ARC 1905 and E 10030 in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of anti-VEGF resistant wet age-related macular degeneration

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Avacincaptad pegol (Primary) ; Pegpleranib (Primary) ; Vascular endothelial growth factors inhibitors
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 According to an OphthoTech Corporation media release, due to a new study design and updated enrollment criteria, the Company will cease enrollment in this study and initiate a new Phase 2a clinical trial.
    • 27 Jan 2016 Status changed from planning to recruiting, according to an OphthoTech Corporation media release.
    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top